Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 930 of 6351
-
New immune drug shows promise in early trial for Hard-to-Treat cancers
Disease control OngoingTransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2 β/γ as monotherapy or in combination therapy in ad…
Phase 1/2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for aggressive breast cancer: drug combo aims to wipe out tumors before surgery
Disease control OngoingThis study aims to investigate efficacy and safety of neoadjuvant toripalimab plus docetaxel and carboplatin in patients with localized triple-negative breast cancer.
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy aims to shrink head and neck tumors before surgery
Disease control OngoingThe purpose of this study is to evaluate the efficacy of neoadjuvant immunoradiotherapy (NIRT) prior to surgery for the treatment of stage III and IVA HPV- HNSCC.
Phase 2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug cocktail shows promise for Hard-to-Treat myeloma
Disease control OngoingThis is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists of 28-day cycles of isatuximab …
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo therapy shows promise for tough liver cancer
Disease control CompletedThe purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy combined with Lenvatinib and PD-1 inhibitors compared to Lenvatinib plus PD-1 inhibitors for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)…
Phase 2 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can a phone app and 800-Calorie diet reverse type 2 diabetes?
Disease control CompletedThis is a multicentre, open-label Randomised Controlled Trial run in the United Kingdom. The main aims are to assess whether the Habitual Remission Programme (digital therapeutics + 12-week 800kcal/day low-energy diet, delivered remotely) is more likely to lead to weight loss and…
Sponsor: Habitual Health Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:00 UTC
-
New hope for tough lymphoma: targeted drug shows promise
Disease control CompletedThe purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, si…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New hope for hard-to-treat lung cancer: drug combo aims to shrink tumors
Disease control OngoingThis multi-center, open label Phase II/III clinical study is performed in patients with locally advanced/metastatic NSCLC progressed on prior EGFR-TKI treatment or with non TKI-sensitizing mutation or patients with EGFR exon20ins mutation. This study is investigating the safety a…
Phase 2/3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Triple therapy targets tough lung cancer
Disease control OngoingA phase II study to assess the efficacy and safety of Surufatinib Combined With Toripalimab and Chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
Phase 2 • Sponsor: Li Zhang, MD • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Custom-Made vaccine aims to stop prostate cancer recurrence
Vaccine OngoingThis proof of concept study is designed to test the safety and tolerability of PGV001-based personalized multi-peptide vaccines in combination with CDX-301 in subjects with a history of aggressive prostate cancer, in the tumor free adjuvant setting.
Phase 1 • Sponsor: Ashutosh Kumar Tewari • Aim: Vaccine
Last updated Jun 27, 2026 08:09 UTC
-
New combo therapy aims to outperform standard drugs for rare blood cancer
Disease control Recruiting nowThis phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Could a kidney cell injection slow Diabetes-Related kidney failure?
Disease control OngoingThe purpose of this study is to assess the safety and efficacy of up to 2 REACT/rilparencel injections in participants with T2DM and CKD.
Phase 3 • Sponsor: Prokidney • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New targeted pill shows promise for Hard-to-Treat lung cancers
Disease control Recruiting nowPhase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced R…
Phase 1/2 • Sponsor: Nuvalent Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Implantable device could offer new hope for patients with untreatable chest pain
Disease control Recruiting nowTo demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribut…
Sponsor: Shockwave Medical, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New shot aims to slash COPD attacks in former smokers
Disease control CompletedThe purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Parti…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a Clot-Boosting drug beat adrenaline for airway bleeding?
Disease control CompletedDuring bronchoscopy (a procedure using a thin, flexible camera to look inside the airways), doctors sometimes take small tissue samples (biopsies) to diagnose lung conditions. This can cause bleeding in the airway. Doctors currently use a medicine called adrenaline to stop this b…
Sponsor: Sheikh Zayed Federal Postgraduate Medical Institute • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a five-day pill course cut COVID-19 deaths? czech nationwide data puts molnupiravir to the test.
Disease control CompletedThis retrospective real-world target trial emulation uses complete Czech nationwide registry data to evaluate whether molnupiravir treatment is associated with lower COVID-19 mortality during the Omicron era. The study compares adults with confirmed acute COVID-19 treated with mo…
Sponsor: Charles University, Czech Republic • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Personalizing sleep apnea treatment: a step toward better CPAP outcomes
Knowledge-focused CompletedMillions of Americans suffer from high blood pressure, diabetes, strokes and motor vehicle accidents due to ineffective treatment of obstructive sleep apnea (OSA). Our preliminary data suggest that physiological causes of OSA such as easy arousability (low arousal threshold) or u…
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Prescribing food: could a diet of medically tailored meals tame diabetes?
Disease control CompletedThe primary purpose of this study is to determine if the implementation of a food as medicine program would improve clinical outcomes when integrated into routine care at two large academic hospitals. 1. Determine if the FRESH Program's methods of addressing food insecurity impr…
Sponsor: Indiana University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Heat therapy as a palliative aid: does raising body temperature ease advanced cancer symptoms?
Symptom relief Recruiting nowThis ambispective observational cohort study will evaluate biological changes, palliative outcomes, and safety associated with ET-SPACE whole-body infrared hyperthermia in patients with advanced solid tumors. This noninvasive treatment uses infrared energy to raise body temperatu…
Sponsor: Zhejiang Hospital • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC